Skip to content
Back to explorer
Printable monograph

Antimetabolite (oral 5-FU prodrug)

Doxifluridine

Furtulon · 5dFUR

Antimetabolite (oral 5-FU prodrug) · approved 1987 · 4 citations

Aging evidence· through 2021
Fairly sourced5/9 · 4 signals
  • Not met: 4 citations
  • Not met: 12+ references
  • Met: Accrued over 10+ years (span: 36y)
  • Met: Beyond single case reports
  • Met: High-impact journal
  • Met: Landmark reference
  • Not met: Current through 2021
  • Not met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

Oral 5-FU prodrug (5'-deoxy-5-fluorouridine) with a measurable renal clearance component; kidney risk is conservative and class-level.

Moderateestablished
Gastrointestinal cancers including colorectal and gastric cancer (regional use, primarily Japan/Asia)Breast cancer (regional use)

Kidney summary

Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.

Renal dosing
Caution — no defined threshold
Consider caution/dose reduction in significant renal impairment (renal clearance component; renally eliminated 5-FU metabolites)
The atlas summary, paraphrased — not label text. Dosing section.
Hemodialysis
Unknown
Dialyzability not well characterized; use caution/consider reduction in significant renal impairment given a renal clearance component and renal 5-FU metabolite elimination.
The atlas summary. Full prose in the Dialyzability section.
FDA boxed warning
No FDA label excerpt in the atlas.
§01

Signature kidney injury

No drug-specific nephrotoxicity incidence is established. Renal risk is inferred at the fluoropyrimidine-class level (rare TMA/HUS); direct doxifluridine renal injury reports are sparse.Source: Gupta et al., Adv Chronic Kidney Dis 2021 (class-level)

Onset & rechallenge

Time to injuryDelayed (>6 weeks / cumulative)

Class-level TMA typically after prolonged cumulative exposure.

Distilled from: “Variable; class-level TMA typically after prolonged cumulative exposure.”

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

  1. Thrombotic Microangiopathy#1 · Signaturequalitative — no citable incidence

    Endothelial injury with microvascular thrombi, hemolysis and thrombocytopenia — gemcitabine, mitomycin C, anti-VEGF.

  2. Electrolyte DisturbanceSecondaryqualitative — no citable incidence

    Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).

  3. Prerenal / Hemodynamic AKISecondaryqualitative — no citable incidence

    Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.

Toxicity fingerprint

Tap a signature to trace where it strikes the nephron.

Incidence not quantified
SeverityModerate
ReversibilityVariable
Evidence4 citations
Nephron map

Thrombotic Microangiopathy strikes: Glomerulus, Vasculature / Endothelium.

Glomerulus — struck by Thrombotic MicroangiopathyFiltration barrier (podocytes + endothelium)
Vasculature / Endothelium — struck by Thrombotic MicroangiopathyGlomerular & peritubular capillaries
Distal Tubule / Collecting Duct — not involved

Thrombotic Microangiopathy

Endothelial injury with microvascular thrombi, hemolysis and thrombocytopenia — gemcitabine, mitomycin C, anti-VEGF.

§03

Kidney injury

Mechanism of kidney injury

As a 5-FU prodrug, doxifluridine carries the fluoropyrimidine-class potential for endothelial injury and rare thrombotic microangiopathy. Pharmacokinetic data show renal excretion is a major but not dominant elimination route (Schaaf 1988: renal clearance 0.32 l/min against nonrenal 0.60 l/min at the lower dose, and 0.29 against 0.37 l/min after doubling — the renal share rises as the saturable nonrenal pathway is exceeded), so reduced kidney function could increase parent-drug and 5-FU exposure and the risk of systemic toxicity. Most renal events are likely prerenal/electrolyte-related from chemotherapy GI toxicity rather than direct tubular injury.

Clinical presentation

Generally renally well tolerated. If TMA/HUS occurs (class effect): microangiopathic hemolytic anemia, thrombocytopenia, rising creatinine, hypertension. Volume depletion from diarrhea/vomiting can cause prerenal azotemia.

Management

For suspected fluoropyrimidine-associated TMA, stop the drug and provide supportive care (blood pressure control, transfusion, renal support/dialysis as needed) with nephrology/hematology input. Manage prerenal AKI with volume resuscitation and electrolyte correction.Lesion-level management framework

Risk factors

  • Renal impairment (reduced clearance of parent drug and 5-FU)
  • Concurrent TMA-associated agents (e.g., mitomycin C)
  • Volume depletion from GI toxicity
  • Higher cumulative fluoropyrimidine exposure

Prevention

  • Use caution in renal impairment given the renal clearance component
Anticancer mechanism· how it treats cancer

5'-Deoxy-5-fluorouridine is a prodrug converted to 5-fluorouracil, predominantly by pyrimidine nucleoside phosphorylase (thymidine phosphorylase), which is often elevated in tumor tissue. The liberated 5-FU is metabolized to FdUMP and FUTP, inhibiting thymidylate synthase and disrupting RNA/DNA synthesis.

Note · Renal data are thin and class-level, with no robust doxifluridine-specific nephrotoxicity literature. PK evidence (Schaaf 1988) is the basis for the renal-clearance caution.
§04

Clinical depth

Renal dose adjustment

No validated renal nomogram. Given a documented renal clearance component for doxifluridine and renal elimination of 5-FU metabolites, consider caution/dose reduction in significant renal impairment per regional labeling.

Dialyzability & ESKD dosing

Not well characterized; dialysis is supportive for AKI rather than established for drug removal.

Differential diagnosis

Separate class-level TMA from other TMA etiologies, prerenal AKI from GI losses, and obstructive uropathy from underlying malignancy.

Monitoring

  • CBC with peripheral smear if TMA suspected
  • LDH

Key trials & series

  • No nephrotoxicity-endpoint trial. Pharmacokinetic study (Schaaf 1988, PMID 2974418) characterizes renal vs nonrenal clearance, underpinning renal-impairment caution.

Clinical pearls

  • PK data show a real renal clearance component — do not assume the kidney is irrelevant in renal impairment.
  • Renal toxicity is class-level and rare; reserve TMA workup for the right hematologic clues.
Beyond the kidney — non-renal toxicities· 4 organ systems

Class-level context for the major non-renal toxicities of the Antimetabolite (oral 5-FU prodrug) class.

Gastrointestinal

Diarrhea, colitis, mucositis, perforation

  • Mucositis and diarrhea

Hepatic / Liver

Transaminitis, hepatitis, VOD/SOS

  • Transaminitis (methotrexate)

Hematologic

Cytopenias, thrombosis, TMA

  • Myelosuppression

Pulmonary

Pneumonitis, ILD, effusions, hypertension

  • Methotrexate / gemcitabine pneumonitis
§05

References

4 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.

Evidence accrual

4 references · 1985–2021 · 1 since 2019
101985: 1 citation1988: 1 citation2017: 1 citation2021: 1 citation19851990200020102021

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

  1. 1.Pharmacology of 5'-deoxy-5-fluorouridine in patients with resistant ovarian cancer.de Bruijn EA, van Oosterom AT, Tjaden UR, Reeuwijk HJ, Pinedo HM · Cancer Res · 1985 · PMID 2932219PK study of doxifluridine (5'-deoxy-5-fluorouridine) showing that renal impairment (low creatinine clearance) reduces renal excretion and prolongs drug exposure and toxicity.
  2. 2.The pharmacokinetics of doxifluridine and 5-fluorouracil after single intravenous infusions of doxifluridine to patients with colorectal cancer.Schaaf LJ et al. · Eur J Clin Pharmacol · 1988 · PMID 2974418Demonstrates that doxifluridine has a substantial renal clearance component alongside nonrenal elimination, supporting caution in renal impairment.
  3. 3.LandmarkConventional Chemotherapy Nephrotoxicity.Gupta S et al. · Adv Chronic Kidney Dis · 2021 · PMID 35190107Onconephrology review of conventional chemotherapy renal effects (TMA, electrolyte disturbance) supporting the class-level framing of fluoropyrimidine prodrugs.
  4. 4.LandmarkAcute Kidney Injury in Patients with Cancer.Rosner MH et al. · N Engl J Med · 2017 · PMID 28467867Comprehensive cancer-AKI review covering drug-induced TMA and prerenal/electrolyte mechanisms relevant to doxifluridine.

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 225 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

  • Renal phenotypes — the same question asked separately for each kind of kidney injury, so the ratios differ from the overall one and from each other.
  • Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.
FAERS reported renal phenotypes· 1 signal

Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.

What reporting says about this profile's documented lesions

  • Thrombotic MicroangiopathyNo disproportionate reporting — This phenotype IS reportable and this agent has enough reports, yet the reporting is not disproportionate — the one genuinely informative negative of the four.
  • Electrolyte DisturbanceNo disproportionate reporting — This phenotype IS reportable and this agent has enough reports, yet the reporting is not disproportionate — the one genuinely informative negative of the four.
  • Prerenal / Hemodynamic AKINot queried in FAERS — No MedDRA term set is defined for this phenotype, so FAERS was never asked about it.
Fanconi Syndrome
ROR 36.8295% CI 9.15–148.19· 2 reports· IC025 −0.42 · IC025 does not clear 0
FAERS outcomes & reporting trend· 6.7% of reports w/ death · 8.4% w/ hospitalization

Counted by the report's active-substance field, which FAERS fills almost only on reports received from 2013 on, so these figures describe reports since then, not the agent's whole history.

6.7%

Reported with a death outcome

15 of 225 reports

8.4%

Reported with hospitalization

19 of 225 reports

Reports per year

  • 2015: 2 reports
  • 2016: 7 reports
  • 2017: 3 reports
  • 2018: 2 reports
  • 2019: 164 reports
  • 2020: 11 reports
  • 2021: 12 reports
  • 2022: 1 reports
  • 2023: 1 reports
  • 2024: 4 reports
  • 2025: 0 reports
  • 2026: 2 reports

Reports received per year, 2015–2026 · most recent year is partial · 16 of the 225 reports predate 2015 and are not drawn.

FAERS adverse-event signal — all organ systems· 11 systems · 225 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. Showing the top 10 of 11 classified systems; 1 lower-ranked system is not drawn. As of 2026-11-15.

Gastrointestinal
Nausea24Diarrhoea23Vomiting17Gastrointestinal Motility Disorder12Abdominal Distension9
Nervous system
Paraesthesia34Neuropathy Peripheral22Dysgeusia9Neurotoxicity8
Skin
Dermatitis Acneiform32Skin Fissures16Dry Skin15Palmar-Plantar Erythrodysaesthesia Syndrome10
General / constitutional
Asthenia36Oedema13
Blood & lymphatic
Anaemia15Thrombocytopenia13
Musculoskeletal
Osteonecrosis Of Jaw11Muscle Contractions Involuntary10
Metabolic & electrolyte
Decreased Appetite15
Hepatobiliary
Hypertransaminasaemia14
Respiratory
Dyspnoea12
Vascular
Flushing12
Guidelines & consensus· 14

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Doxifluridine sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.
Phenotype-similar agents· the numbered markers on the map above

Carmofur (HCFU)

Mifurol · Antimetabolite (oral 5-FU prodrug)

Profile

Lipophilic oral 5-FU prodrug (Japan); class-level renal risk; hallmark toxicity is leukoencephalopathy not nephropathy.

TMALYTEPRE
Moderate#1 · 100% phenotype match

Tegafur-uracil (UFT)

UFT · Antimetabolite (oral 5-FU prodrug)

Profile

Oral tegafur+uracil; rare fluoropyrimidine-class TMA/HUS (often with mitomycin C), otherwise kidney-sparing.

TMALYTEPRE
Severe#2 · 94% phenotype match

Daraxonrasib

Rasonque · RAS(ON) multi-selective inhibitor

Profile

2026 first RAS(ON) inhibitor (mutant + wild-type RAS) for pretreated metastatic pancreatic cancer; creatinine rose in 24% vs 9% on chemotherapy beside 67% diarrhea, and the label names one renal-limited TMA.

PRELYTETMA
Moderate#3 · 86% phenotype match

Ruxolitinib

Jakafi · JAK1/2 inhibitor

Profile

Tumor lysis in myelofibrosis; renally adjusted.

PRELYTETMA
Mild#4 · 70% phenotype match

Decitabine

Dacogen · Hypomethylating agent

Profile

Tumor lysis in MDS/AML.

XTALPRELYTE+1 more
Mild#5 · 67% phenotype match

Capecitabine

Xeloda · Pyrimidine analog (oral 5-FU)

Profile

Diarrhea-driven prerenal AKI; dose-adjust for CrCl.

PRETMA
Mild#6 · 67% phenotype match
Compare Doxifluridine with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across Antimetabolites

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.

  1. 1CapecitabineMild
  2. 2CladribineMild
  3. 35-FluorouracilFAERS AKIMild
  4. 4HydroxyureaFAERS AKIMild
  5. 4NelarabineFAERS AKIMild
  6. 6DecitabineFAERS AKIMild
  7. 7Trifluridine/tipiracilModerate
  8. 8PralatrexateModerate
  9. 9Carmofur (HCFU)FAERS n/aModerate
  10. 9Doxifluridine· this agentModerate
  11. 11Methotrexate (high-dose)FAERS AKIModerate
  12. 11RaltitrexedFAERS AKIModerate
  13. 13FludarabineFAERS AKIModerate
  14. 13PentostatinFAERS AKIModerate
  15. 15AzacitidineFAERS AKIModerate
  16. 15ClofarabineFAERS AKIModerate
  17. 15CytarabineFAERS AKIModerate
  18. 15PemetrexedFAERS AKIModerate
  19. 19Tegafur-uracil (UFT)Severe
  20. 20GemcitabineFAERS AKISevere

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.